TMIGD2 knockdown and anti-TMIGD2 mAb treatment compromised LSCs and impeded leukemogenesis in PDX models of refractory/relapsed AML, underscoring the therapeutic value of targeting TMIGD2 in AML. Here, TMIGD2 is linked to acute myeloid leukemia.